Retatrutide is supplied by RS Bio Labs strictly as a laboratory research material. It is not approved, intended or authorised for human consumption or any therapeutic use, and RS Bio Labs products are not FDA-approved medicines. This article is written for qualified researchers and is not medical advice.
The short answer, and why the question keeps coming up
Retatrutide is not FDA-approved. It has not been approved by the MHRA, the FDA, or any other regulator, for any indication. It is an investigational compound in active Phase 3 development by Eli Lilly, and until those trials report and a regulator reviews them, its status will not change. The reason people keep asking is straightforward: the early data was so striking that it is easy to assume approval must have followed. In the Phase 2 TRIUMPH-1 obesity trial the highest dose produced roughly 24.2% mean body-weight reduction at 48 weeks — the largest figure reported for any incretin-class compound to date, and, notably, a curve that had not plateaued when the study ended. Headline results, however, are not the same thing as regulatory approval, and conflating the two is precisely the confusion this page exists to clear up. For the full evidence base, see our Retatrutide research summary.
What "investigational" and "Phase 3" actually mean
An investigational compound is one that is still being studied and has not been authorised for sale or use as a medicine. Its safety and efficacy for any approved purpose have not been established to a regulator's satisfaction — the very thing clinical trials exist to determine. Retatrutide sits at the last research stage before that decision point: Phase 3.
The clinical-trial pipeline runs in sequence. Phase 1 establishes basic tolerability and pharmacokinetics in a small group — for Retatrutide this was the first-in-human work of the early 2020s, which confirmed the roughly six-day half-life that supports a once-weekly schedule. Phase 2 tests efficacy and dose-response in a larger population; this is where TRIUMPH-1 delivered its landmark obesity result, alongside parallel readouts in type 2 diabetes and liver disease. Phase 3 is the pivotal stage: large, long, multi-site trials designed to confirm the Phase 2 effect, characterise longer-term safety, and — increasingly a standard expectation for metabolic compounds — establish hard clinical outcomes such as cardiovascular endpoints. Retatrutide's Phase 2 programme is complete and reported; its Phase 3 TRIUMPH programme is ongoing. You can read how it got here in our history of Retatrutide.
The approval pathway still ahead
Being in Phase 3 does not mean approval is imminent, and it certainly does not mean approval is guaranteed. Several steps still separate Retatrutide from an approved label. The pivotal Phase 3 trials must first read out — reach their pre-defined endpoints and report their data. A developer then compiles that evidence into a regulatory submission (in the United States, a New Drug Application to the FDA). The regulator reviews the full dataset, may convene advisory input, and either approves, requests more information, or declines. Only if it approves, and only for the specific indications and doses the data supports, does a compound become an approved medicine.
We are not going to put a date on any of that, because there is nothing to report: as of 2026 no FDA decision, approval, or advisory outcome for Retatrutide has occurred. Anyone who tells you otherwise is guessing. The honest, verifiable position is simply this — Phase 3 is underway, and the outcome is pending.
Approved vs investigational: where the incretin class actually stands
The clearest way to answer "is Retatrutide approved?" is to place it beside the compounds that are. As of 2026, only two molecules in the incretin class are FDA-approved medicines; the rest — Retatrutide included — remain investigational. The table below sets out the difference.
| Compound | Receptor targets | Furthest stage | 2026 FDA status |
|---|---|---|---|
| Semaglutide | GLP-1 (single) | Approved & marketed | FDA-approved (Ozempic / Wegovy) |
| Tirzepatide | GIP + GLP-1 (dual) | Approved & marketed | FDA-approved (Mounjaro / Zepbound) |
| Retatrutide | GIP + GLP-1 + glucagon (triple) | Phase 3 (TRIUMPH) | Investigational — not approved |
| Survodutide | GLP-1 + glucagon (dual) | Phase 3 | Investigational — not approved |
| Mazdutide | GLP-1 + glucagon (dual) | Phase 3 | Investigational — not approved |
Read across the table and the point lands: the two approved molecules, Semaglutide and Tirzepatide, carry mature datasets that have already cleared regulatory review. Retatrutide, for all the excitement around its numbers, sits in the same "investigational" column as Survodutide and Mazdutide — further along in some respects, but on the same side of the approval line. For the mechanistic head-to-head, see our Semaglutide vs Tirzepatide vs Retatrutide comparison.
Why an unapproved molecule is the most-watched in its class
If it is not approved, why does Retatrutide dominate the conversation? Because it is the only triple agonist of the group. Semaglutide activates one receptor and Tirzepatide two; Retatrutide adds a third — the glucagon receptor — on top of GIP and GLP-1. The GLP-1 and GIP arms reduce energy intake through appetite suppression and glucose-dependent insulin release, while the glucagon arm is studied as a mechanism for raising resting energy expenditure. No single- or dual-agonist compound does both at once, and that "energy-in, energy-out" design is what researchers believe underpins the largest Phase 2 weight reduction seen in the class. In other words, its status as the most-watched molecule and its status as investigational are not in tension — it is watched because its Phase 3 outcome is the open question the whole field is waiting on. Our full Retatrutide research profile covers the mechanism in depth.
What this means for research supply
The distinction matters for how the compound is legitimately handled. Because Retatrutide is not an approved medicine, it cannot be sold, prescribed or used as one. It is, however, entirely legitimate as a research reagent: material supplied for qualified scientific personnel to use in in vitro laboratory work. That is the only basis on which RS Bio Labs supplies it. Our Retatrutide is offered strictly for in vitro research use, third-party HPLC tested to ≥99% purity, and is not for human consumption, self-administration or therapeutic use of any kind. Nothing on this page is medical advice, and nothing here should be read as suggesting Retatrutide is a treatment. Researchers who need the material can see live pricing and strengths on our buy Retatrutide UK page.
The bottom line
Is Retatrutide FDA-approved? No. As of 2026 it is an investigational triple GIP/GLP-1/glucagon agonist in Phase 3 development — the pivotal TRIUMPH programme — with no FDA approval, decision or date to report. Only Semaglutide and Tirzepatide are approved medicines in this class; Retatrutide, Survodutide and Mazdutide remain investigational. It is the most-watched molecule in the field precisely because its Phase 3 readouts are still pending, not because approval has arrived. For research-grade material, see our page to buy Retatrutide UK, ≥99% purity and for in vitro use only.
